Successful entry of MS Medical Allied Services on NSE mainboard; 500 crore revenue target by 2029!

QMS Medical Allied Services Limited (NSE Symbol: QMSMEDI; ISIN: INE0FMW01018), a leading provider of integrated healthcare solutions, today announced its successful listing on the Mainboard of the National Stock Exchange (NSE). This is considered as an important step in the development journey of the company. QMS was listed on NSE Emerge on 11 October 2022 after a successful SME IPO. 1.93 crore equity shares (face value ₹10 each) of the company have become available for trading on NSE from today, June 18, 2026 after completion of migration to mainboard. The share price of the company was ₹ 108.95 at the opening of trading today.

Gold Hallmark Magic: Lost gold jewelry… Don’t get tensed now! Searching has become easy due to ‘this’ technology, know in detail

Strong presence in pharma marketing sectors

The upgrade was achieved on the back of consistent performance and strong growth in the company’s manufacturing and services businesses. In FY2026, the company reported consolidated revenue of ₹172.9 crore and EBITDA of ₹25.9 crore. It is the only listed company with a strong presence and significant market share in the fast growing preventive healthcare management and pharma marketing sectors. Therefore, the company has created a unique position in this field. Inclusion in the NSE mainboard is expected to help increase the liquidity of the share, increase the participation of institutional and retail investors and strengthen the company’s visibility in the capital market.

Consistent emphasis on long-term value creation

Speaking about this milestone, the Chairman and Managing Director of QMS Medical Allied Services Limited, Shri. Mahesh Makhija said, “Our listing on the NSE Mainboard is an important milestone in the growth journey of QMS and is a symbol of the strong foundation we have built over the years. We are deeply grateful to our stakeholders, customers, employees and business partners who have played an important role in our journey. Post listing on NSE Emerge, we have continued to focus on expanding our operations, adhering to strong governance standards and creating long-term value for all stakeholders.”

We aim to triple our income in three years

He added, “India’s healthcare sector is undergoing unprecedented transformation and the demand for integrated healthcare and pharma marketing solutions is growing rapidly. This is shifting the focus from product-centric communication to patient-centric communication. Our consistent efforts to strengthen and expand our presence in both product and service business segments has given us a competitive edge to successfully grow in a globally opportunistic, fast-evolving and high-demand market. We have set a target of tripling our revenue in the next three years.”

Over the years, QMS has built a strong presence in the healthcare value chain. The company has served over 10 lakh patients and has partnered with over 50 leading pharmaceutical and healthcare companies across India. The company is continuously working to make healthcare more accessible through patient assistance programs, healthcare services, medical and diagnostic solutions, healthcare manpower and integrated patient communication initiatives.

A consolidated revenue target of ₹500 crore by FY 2029

Over the past four years, the company has transformed itself from a purely product-focused business to an integrated healthcare solutions provider that includes products, services and patient interaction capabilities. The company is particularly focused on medical and diagnostic solutions. QMS has strengthened its product portfolio by introducing its own brand ‘Q-Devices’. At the same time, it has developed deeper relationships with various healthcare organizations by expanding distribution partnerships. On the other hand, reaching patients more effectively, improving treatment outcomes and providing consistent patient management through integrated healthcare are gaining increasing importance in the pharmaceutical industry. To complement these needs, the company has also rapidly grown its services business. At the end of FY 2026, 69 percent of the company’s total revenue came from the manufacturing business.
Recognizing the growing importance of increasing patient reach, improved treatment outcomes and consistent patient management in the pharmaceutical industry, the company expanded into the areas of patient services and healthcare engagement solutions. This includes patient screening camps. The company further strengthened its services business by acquiring a controlling stake in Sarathi Healthcare, a leader in patient and disease management, market access and physical healthcare solutions. The acquisition significantly enhanced QMS’s capabilities in Patient Service Programs (PSP) and integrated healthcare. This enables the company to handle the entire process from conceptualization of programs to implementation and scale-up. As the adoption of PSP among pharmaceutical companies in India continues to grow, QMS expects to double its services business revenue by FY 2027 on the back of growing partnerships and a strong order pipeline.
QMS is expected to triple its consolidated revenue by FY 2029 on the back of two strong pillars – a reliable and scalable manufacturing business and a rapidly growing and future-ready services portfolio.

Hormuz Strait Crisis: …then America would have been in enough trouble! Oil inventories at 43-year low